Evolus (EOLS) Competitors $6.63 -0.56 (-7.79%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$6.84 +0.21 (+3.11%) As of 06:52 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock EOLS vs. IMCR, APGE, SRPT, AUPH, CDTX, VCEL, PAHC, ARDX, TWST, and VERAShould you be buying Evolus stock or one of its competitors? The main competitors of Evolus include Immunocore (IMCR), Apogee Therapeutics (APGE), Sarepta Therapeutics (SRPT), Aurinia Pharmaceuticals (AUPH), Cidara Therapeutics (CDTX), Vericel (VCEL), Phibro Animal Health (PAHC), Ardelyx (ARDX), Twist Bioscience (TWST), and Vera Therapeutics (VERA). These companies are all part of the "pharmaceutical products" industry. Evolus vs. Its Competitors Immunocore Apogee Therapeutics Sarepta Therapeutics Aurinia Pharmaceuticals Cidara Therapeutics Vericel Phibro Animal Health Ardelyx Twist Bioscience Vera Therapeutics Evolus (NASDAQ:EOLS) and Immunocore (NASDAQ:IMCR) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, media sentiment, profitability, analyst recommendations, risk and valuation. Which has stronger earnings & valuation, EOLS or IMCR? Evolus has higher earnings, but lower revenue than Immunocore. Immunocore is trading at a lower price-to-earnings ratio than Evolus, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEvolus$266.27M1.61-$50.42M-$0.98-6.77Immunocore$310.20M5.59-$51.09M-$0.40-86.05 Is EOLS or IMCR more profitable? Immunocore has a net margin of -5.70% compared to Evolus' net margin of -22.31%. Immunocore's return on equity of -5.40% beat Evolus' return on equity.Company Net Margins Return on Equity Return on Assets Evolus-22.31% -759.04% -24.63% Immunocore -5.70%-5.40%-1.93% Do institutionals and insiders believe in EOLS or IMCR? 90.7% of Evolus shares are owned by institutional investors. Comparatively, 84.5% of Immunocore shares are owned by institutional investors. 6.1% of Evolus shares are owned by company insiders. Comparatively, 10.4% of Immunocore shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Do analysts recommend EOLS or IMCR? Evolus currently has a consensus target price of $21.25, indicating a potential upside of 220.51%. Immunocore has a consensus target price of $56.89, indicating a potential upside of 65.28%. Given Evolus' stronger consensus rating and higher possible upside, equities analysts plainly believe Evolus is more favorable than Immunocore.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evolus 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75Immunocore 1 Sell rating(s) 4 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.45 Which has more volatility and risk, EOLS or IMCR? Evolus has a beta of 1.07, indicating that its share price is 7% more volatile than the S&P 500. Comparatively, Immunocore has a beta of 0.77, indicating that its share price is 23% less volatile than the S&P 500. Does the media prefer EOLS or IMCR? In the previous week, Evolus had 2 more articles in the media than Immunocore. MarketBeat recorded 7 mentions for Evolus and 5 mentions for Immunocore. Immunocore's average media sentiment score of 1.03 beat Evolus' score of 0.79 indicating that Immunocore is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evolus 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immunocore 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryImmunocore beats Evolus on 9 of the 16 factors compared between the two stocks. Get Evolus News Delivered to You Automatically Sign up to receive the latest news and ratings for EOLS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EOLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EOLS vs. The Competition Export to ExcelMetricEvolusMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$465.09M$10.74B$5.80B$10.16BDividend YieldN/A1.86%5.72%4.60%P/E Ratio-6.7720.5675.1326.39Price / Sales1.6129.77508.32174.86Price / CashN/A25.0025.8129.91Price / Book73.673.4313.716.28Net Income-$50.42M$210.63M$3.29B$270.38M7 Day Performance-10.28%-1.46%0.07%1.89%1 Month Performance-1.49%1.65%4.57%6.01%1 Year Performance-60.47%-11.43%78.24%25.26% Evolus Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EOLSEvolus4.0518 of 5 stars$6.63-7.8%$21.25+220.5%-62.1%$465.09M$266.27M-6.77170Positive NewsIMCRImmunocore1.8695 of 5 stars$34.42-2.3%$56.89+65.3%+2.6%$1.78B$310.20M-86.05320APGEApogee Therapeutics2.8896 of 5 stars$36.86-0.1%$97.29+163.9%-28.3%$1.70BN/A-8.9291Positive NewsSRPTSarepta Therapeutics4.4246 of 5 stars$17.47+0.5%$39.32+125.1%-86.0%$1.70B$1.90B-20.081,372Positive NewsAnalyst ForecastAUPHAurinia Pharmaceuticals2.915 of 5 stars$12.81+0.5%$12.00-6.3%+82.2%$1.68B$235.13M29.79300Positive NewsCDTXCidara Therapeutics3.1779 of 5 stars$66.91+2.0%$64.14-4.1%+460.4%$1.66B$1.27M-6.0190Positive NewsHigh Trading VolumeVCELVericel2.7424 of 5 stars$31.42-2.4%$60.40+92.2%-31.5%$1.62B$237.22M261.86300Positive NewsPAHCPhibro Animal Health4.446 of 5 stars$39.53-0.2%$28.40-28.2%+79.8%$1.61B$1.30B33.502,475ARDXArdelyx4.6261 of 5 stars$6.53-1.2%$11.70+79.2%+3.5%$1.59B$333.61M-28.3990Positive NewsTWSTTwist Bioscience3.9661 of 5 stars$25.72+1.6%$49.40+92.1%-45.2%$1.53B$312.97M-17.74990VERAVera Therapeutics2.8558 of 5 stars$24.24+2.0%$63.00+159.9%-35.4%$1.52BN/A-6.7740Positive News Related Companies and Tools Related Companies Immunocore Competitors Apogee Therapeutics Competitors Sarepta Therapeutics Competitors Aurinia Pharmaceuticals Competitors Cidara Therapeutics Competitors Vericel Competitors Phibro Animal Health Competitors Ardelyx Competitors Twist Bioscience Competitors Vera Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EOLS) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersNew Biotech Backed by Proven Incubator Now Open to PublicA successful biotech incubator just opened its next chapter - and you're invited to their raise. This deal ...i2i Marketing Group, LLC | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredThis Coin Could Explode, and it’s Hiding in Plain Sight!The #1 coin with skyrocket potential right now... Sometimes the biggest opportunities are hiding in plain s...Crypto 101 Media | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredDalio’s $319 Million Gold BetA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredIf you own dollars, read this...Former Goldman Exec: "A Strange Day Is Coming to America" Dr. David Eifrig, who warned of inflation months ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evolus, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Evolus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EOLS Stock Alerts